There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
Inspection Record
MSD Ireland (Carlow) — FDA 483 Findings
Inspectors Laurel A Beer · Travis S BradleyThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Fresenius Kabi Oncology Limited2023-10-10 · US FDASimilar to finding 1 There is a failure to thoroughly review any unexplained discrepancy whether or not the batch has been already distributed.
- Berkshire Sterile Manufacturing2024-10-21 · US FDASimilar to finding 2 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- ADMA Biologics, Inc2024-12-11 · US FDASimilar to finding 2 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- Serum Institute of India Pvt. Ltd.2022-04-19 · US FDASimilar to finding 2 Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
- Merck Teknika LLC2024-11-27 · US FDASimilar to finding 3 Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and followed.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.